Thinking up tomorrow's medicine
[Presse release] On January 22nd, 2015, bioMérieux announced the acquisition of CEERAM (European Centre for Expertise and Research on Microbial Agents), an innovative molecular virology laboratory specialized in the detection of foodborne and environmental viruses. Ceeram is a member of Atlanpole Biotherapies.
InFlectis BioScience banks €1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases
InFlectis BioScience, a pharmaceutical drug discovery company focused on degenerative diseases caused by protein misfolding and member of Atlanpole Biotherapies, has completed its seed funding round, having raised €1.75 million. A diverse group of investors has been attracted to the potential of the company's approach to hitherto untreatable chronic degenerative diseases such as Charcot-Marie-Tooth disease, Retinitis pigmentosa, and Amyotrophic Lateral Sclerosis. The company shares global rights for the exploitation of a promising candidate drug, IFB-088, with the UK's Medical Research Council (MRC).
[Press release] CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical forms of antibiotics for the targeting of osteoarticular infectious diseases. The agreement includes an out-licensing option to Atlangram for CARLINA’s lipid nanocapsule technology platform SOLUDOTSTM. CARLINA Technologies and Atlangram are both members of Atlanpole Biotherapies.
Meet them there on the French Pavilion.
The 3rd Nuclear Technologies for Health Symposium (NTHS) will take place from 10 to 11 March 2015 in Nantes. This international meeting around radiopharmaceuticals and nuclear medicine is organized by the Labex IRON (Radiopharmaceuticals for Innovative Oncology and Neurology Laboratory of Excellence.
Research, Cancer, Ethics Bioinformatics, Plant science Mitochondrial medicine... Share your knowledge with international researchers and students from different countries and cultures.
The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation.
Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005).